Journal article
Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database
Pal Moller, Toni Seppala, Inge Bernstein, Elke Holinski-Feder, Paola Sala, D Gareth Evans, Annika Lindblom, Finlay Macrae, Ignacio Blanco, Rolf Sijmons, Jacqueline Jeffries, Hans Vasen, John Burn, Sigve Nakken, Eivind Hovig, Einar Andreas Rodland, Kukatharmini Tharmaratnam, Wouter H de Vos Tot Nederveen Cappel, James Hill, Juul Wijnen Show all
GUT | BMJ PUBLISHING GROUP | Published : 2017
Abstract
OBJECTIVE: Estimates of cancer risk and the effects of surveillance in Lynch syndrome have been subject to bias, partly through reliance on retrospective studies. We sought to establish more robust estimates in patients undergoing prospective cancer surveillance. DESIGN: We undertook a multicentre study of patients carrying Lynch syndrome-associated mutations affecting MLH1, MSH2, MSH6 or PMS2. Standardised information on surveillance, cancers and outcomes were collated in an Oracle relational database and analysed by age, sex and mutated gene. RESULTS: 1942 mutation carriers without previous cancer had follow-up including colonoscopic surveillance for 13 782 observation years. 314 patients ..
View full abstractGrants
Awarded by Spanish Ministry of Economy and Competitiveness
Awarded by RTICC
Awarded by Government of Catalonia
Awarded by Cancer Research UK
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Awarded by MRC
Funding Acknowledgements
The Finnish contribution was supported by The Finnish Cancer Foundation, The Sigrid Juselius Foundation, Mary and Georg Ehrnrooth foundation and State Research Funding. The Spanish contribution has been funded by the Spanish Ministry of Economy and Competitiveness SAF2012-33636 (GC); the Carlos III Health Institute; RTICC (RD12/0036/0008); the Scientific Foundation Asociacion Espanola Contra el Cancer; and the Government of Catalonia (2014 SGR 338) and the Welsh Contribution by the Wales Gene Park.